Amphiphilic Janus Nanoparticles for Effective Treatment of Bacterial Pneumonia by Attenuating Inflammation and Targeted Bactericidal Capability
Xiangjun Chen,Weiwei Li,Qing Fan,Xiao Liu,Xuanxiang Zhai,Xiaoyi Shi,Wenting Li,Wei Hong
DOI: https://doi.org/10.2147/ijn.s486450
IF: 7.033
2024-11-27
International Journal of Nanomedicine
Abstract:Xiangjun Chen, &ast Weiwei Li, &ast Qing Fan, Xiao Liu, Xuanxiang Zhai, Xiaoyi Shi, Wenting Li, Wei Hong School of Pharmacy, Shandong Engineering Research Center of New-Type Drug Loading & Releasing Technology and Preparation, Binzhou Medical University, Yantai, Shandong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Hong; Wenting Li, Email ; Introduction: Pseudomonas aeruginosa (P. aeruginosa) -induced pneumonia is marked by considerable infiltration of inflammatory cells and biofilm formation, which causes acute and transient lung inflammation and infection. Nevertheless, the discovery of alternative preventative and therapeutic methods is essential due to the high mortality rates in clinical settings and the resistance of P. aeruginosa infection to multiple medications. Purpose: In this research, we constructed amphiphilic Janus nanoparticles (JNPs, denoted as SSK1@PDA/CaP@CIP), loaded with hydrophobic SSK1, a β-galactosidase (β-gal)-activated prodrug for reducing macrophages, and hydrophilic ciprofloxacin (CIP), a classic antibiotic for treating infection. SSK1@PDA/CaP@CIP was designed to effectively attenuate inflammation, eradicate biofilms, and combat planktonic P. aeruginosa . Results: As expected, SSK1@PDA/CaP@CIP was able to target the infection site and demonstrated outstanding efficacy in treating P. aeruginosa strain PAO1-induced pneumonia by regulating macrophage infiltration to reduce inflammation and removing planktonic bacteria and biofilms to control infection. Additionally, the primary organs did not exhibit any discernible pathological changes following treatment with SSK1@PDA/CaP@CIP, which indicates superior biocompatibility throughout the treatment course. Discussion: In conclusion, our investigation introduced a promising approach to the treatment of pneumonia associated with PAO1. Keywords: Pseudomonas aeruginosa , pneumonia, inflammatory responses, β-galactosidase (β-gal)-activated prodrug, amphiphilic Janus nanoparticles Bacterial pneumonia is the most prevalent type of pneumonia, which is an inflammation of the lungs caused by multiple factors. 1 P. aeruginosa is a major nosocomial infection that usually causes acute pneumonia. It is particularly hazardous to patients with malignancies, hematological diseases, metabolic diseases, and severe infections that necessitate ventilation, such as coronavirus 2019 infection. 2–5 Consequently, P. aeruginosa is a significant pathogenic bacterium causing hospital-acquired pneumonia and is related to with a high clinical mortality rate. 6,7 P. aeruginosa- induced pneumonia can result in a series of events in the host, such as immune cell buildup, reactive oxygen species generation, cytokine release, inflammatory response activation, lipid metabolism disruption, and epigenetic factor modulation. 8–10 These events progressively cause chronic pathological deterioration of the respiratory system. Furthermore, P. aeruginosa has a higher ability to form biofilms, which results in long-term persistence in clinical settings. Self-produced extracellular polymeric substances (EPS) primarily form biofilms, which protect internal bacteria from environmental hazards and inhibit antibiotic penetration. 11–14 As a result, bacteria in biofilm form are more drug-resistant than planktonic cells by up to 10–1000 fold. Due to the highly resistant biofilm and intrinsic resistance, aggressive antibiotic therapy always leads to unsatisfactory outcomes. Thus, effective therapy for P. aeruginosa -induced pneumonia should focus on 3 aspects: killing bacteria, eliminating biofilm, and attenuating inflammation. 15–17 According to research, inflammatory macrophages are the primary cause of pneumonia inflammation because they release an abundant proinflammatory cytokines. Deng et al developed SSK1, a β-galactosidase (β-gal)-activated prodrug that targets macrophages. β-gal expression is a typical response to immune activation. 18 In a lung-injured animal model, SSK1 treatment effectively reduced macrophage numbers and infiltration levels, resulting in a significant alleviation in inflammation. 19 Recently, significant attention has been paid to nanoparticle in the field of medication administration, 20–22 especially s Janus nanoparticles (JNPs). 23,24 Two distinct domains with varying chemical compositions are present in these nanoparticles, which enables the precise calibration and regulation of their properties. Independent divisions can reduce drug interactions and improve treatment efficiency. Due to its -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology